Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Caproates”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 145 records · Page 8Linked to original sources
PubMedDate not supplied

[Diverse action of 17-alpha-hydroxyprogesterone caproate and medroxyprogesterone acetate on the biosynthesis of collagen and cirrhogenous course of CC14-induced hepatic lesions in rats].

The administration of medroxyprogesterone acetate to rats did not induce rapidly progressing cirrhosis in livers damage by carbon tetrachloride, as had occurred after the administration of 17-alpha-hydroxyprogesterone caprate. Even after two months' treatment with medroxyprogesterone acetate and CC14, the cirrhosis did not reach the levels obtained in a single month with the association of 17-alpha-hydroxyprogesterone and CC14.

17 alpha-Hydroxyprogesterone Caproate↗
PubMed1984

[Comparative studies of the effect on the in vitro growth of endometrial cancers of hydroxyprogesterone caproate, norethisterone acetate and D-norgestrel].

The influence of the progestogens hydroxyprogesteroncaproate , norethisteronacetate and d-norgestrel on the growth of endometrial cancer was observed on 78 cell cultures. 40 cases revealed an influence on in vitro growth by at least one progestogen, 26 times by progesterone, 21 times by norethisterone and 20 times by norgestrel. In 17 cases two or more progestogens had an effect on in vitro growth, however, in 23 cases only one progestogen revealed an effect. The possible consequences of these results for the planning of therapy are discussed.

17 alpha-Hydroxyprogesterone Caproate↗
PubMed1980

Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma.

A prospective trial was initiated in 1972 utilizing Depo-Provera in women with metastatic or recurrent endometrial adenocarcinoma to evaluate if the objective response and survival would be significantly improved in comparison to patients previously treated with Delalutin at a similar dose. One hundred fourteen patients were included in the study: 70 received Delalutin and 44 Depo-Provera. There was no significant increase in the objective response or survival between the Delalutin or Depo-Provera patients. Of the 114 patients, 15.8% achieved an objective response, with 7.0% being complete responders. There was no significant increase in objective response to Delalutin or Depo-Provera in relationship to the size of the tumor masses, the number of metastases, site of metastases, histologic grade of the primary, histologic grade of recurrence or metastases, or prior radiation therapy. The only significant correlate was that patients whose disease recurred 3 or more years after the initial therapy had a significant (P = 0.01) increase in response (33.3%) compared to those with recurrence less than 3 years after their original treatment (8.3%).

Adenocarcinoma↗